Scientific publications

Neuroleptic malignant syndrome treated with subcutaneous lisuride infusion
Rodríguez M.E., Luquin M.R., Lera G., Delgado G., Salazar J.M., Obeso J.A.
Department of Neurology, Clínica Universitaria, University of Navarra, Pamplona, Spain
Magazine: Movement Disorders
Date: Jan 1, 1990
Neurology [SP]A schizophrenic patient developed a characteristic clinical picture of neuroleptic malignant syndrome (NMS) while admitted to the hospital during an exacerbation of his psychiatric symptoms. Oral treatment of the NMS with bromocriptine (7.5 mg/day) or levodopa/carbidopa (125/12.5 mg) provoked intense vomiting in spite of domperidone (60 mg/day), which led to their discontinuation. In view of the deterioration of the symptoms, treatment was begun with lisuride (1-2 mg/24 h) subcutaneously. An obvious improvement was shown in 24 h, but levodopa/carbidopa (125/12.5 mg t.d.s. orally) had to be added later to achieve complete resolution of the NMS.
During the recovery phase, while being treated with subcutaneous lisuride infusion and levodopa (p.o.), the patient presented with confusion, agitation, and hallucination. Lisuride infusion was stopped and levodopa was continued until complete resolution of the NMS.
This case indicates that parenteral administration of lisuride or other dopamine agents such as levodopa (i.v.) or apomorphine (s.c.) may be considered an effective and practical way of treating NMS, particularly when the patient's condition makes it difficult or impossible to use other dopaminergic drugs by the oral route.
CITATION Mov Disord. 1990;5(2):170-2
you maybe interested
WHAT TECHNOLOGY
DO WE USE?
The Clínica is the greater private hospital with technological equipment of Spain, all in a single center.

OUR
PROFESSIONALS
The professionals of the Clínica perform continuous research and training, always to the benefit of the patient.

WHY CHOOSE
THE CLINICA?
Learn why we are different from other healthcare centers. Quality, speed, comfort and results.
